AI Engines For more Details: Perplexity Kagi Labs You
Arrhythmia Management: Moricizine hydrochloride is effective in treating various types of ventricular arrhythmias, including ventricular tachycardia and ventricular fibrillation. These arrhythmias can be life-threatening and may lead to sudden cardiac arrest if not properly managed.
Proarrhythmic Effects: While moricizine hydrochloride can be effective in suppressing ventricular arrhythmias, it also has proarrhythmic effects, meaning it can potentially worsen existing arrhythmias or induce new arrhythmias. Patients taking moricizine hydrochloride require careful monitoring of their heart rhythm and may need dose adjustments or discontinuation of the medication if proarrhythmic effects occur.
QT Prolongation: Moricizine hydrochloride can prolong the QT interval on the electrocardiogram (ECG), which is a marker for increased risk of ventricular arrhythmias, including torsades de pointes. Patients with preexisting QT prolongation or other risk factors for arrhythmias should be closely monitored while taking moricizine hydrochloride.
Hemodynamic Effects: Moricizine hydrochloride may have hemodynamic effects, including lowering blood pressure and slowing heart rate. Patients with underlying cardiovascular conditions such as heart failure or bradycardia may require careful monitoring and dose adjustments to prevent adverse effects.
Side Effects: Common side effects of moricizine hydrochloride include dizziness, lightheadedness, fatigue, nausea, and vomiting. These side effects are usually mild and transient but may necessitate dose adjustments or discontinuation of the medication in some cases.
Drug Interactions: Moricizine hydrochloride may interact with other medications, particularly other antiarrhythmic drugs and medications that affect heart rhythm. Patients should inform their healthcare providers about all medications, supplements, and herbal products they are taking to avoid potential drug interactions.
Contraindications: Moricizine hydrochloride is contraindicated in patients with certain medical conditions, including severe heart failure, severe bradycardia, second- or third-degree atrioventricular block, and preexisting QT prolongation. It should also be used with caution in patients with hepatic impairment, as it is metabolized in the liver.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| ADHD | 2.8 | 2.8 | |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 1.6 | 0.5 | 2.2 |
| Allergies | 2.2 | 1.7 | 0.29 |
| Allergy to milk products | 0.8 | 1.3 | -0.63 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 3.7 | 3.3 | 0.12 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.5 | 0.5 | 2 |
| Ankylosing spondylitis | 2.5 | 0.6 | 3.17 |
| Anorexia Nervosa | 1 | 2.1 | -1.1 |
| Antiphospholipid syndrome (APS) | 1.1 | 1.1 | |
| Asthma | 2 | 0.6 | 2.33 |
| Atherosclerosis | 1.4 | 0.6 | 1.33 |
| Atrial fibrillation | 2.2 | 1.9 | 0.16 |
| Autism | 4 | 4.8 | -0.2 |
| Autoimmune Disease | 0.9 | 0.9 | |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.5 | 0.5 | |
| Bipolar Disorder | 1.6 | 0.3 | 4.33 |
| Brain Trauma | 0.3 | 0.6 | -1 |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 0.3 | 0.6 | -1 |
| Carcinoma | 2.2 | 1.3 | 0.69 |
| Celiac Disease | 2.3 | 1.3 | 0.77 |
| Cerebral Palsy | 0.6 | 0.6 | 0 |
| Chronic Fatigue Syndrome | 2.9 | 3.3 | -0.14 |
| Chronic Kidney Disease | 2 | 0.1 | 19 |
| Chronic Lyme | 0.1 | 0.3 | -2 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 0.3 | 1.67 |
| Chronic Urticaria (Hives) | 1.1 | 1.1 | 0 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 0.6 | 1.5 |
| Cognitive Function | 1.3 | 0.6 | 1.17 |
| Colorectal Cancer | 4.2 | 1.1 | 2.82 |
| Constipation | 1.8 | 1.8 | |
| Coronary artery disease | 1.7 | 1.2 | 0.42 |
| COVID-19 | 5.4 | 6.3 | -0.17 |
| Crohn's Disease | 4.8 | 2 | 1.4 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.8 | 0.3 | 1.67 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 1.4 | 0.9 | 0.56 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 5.4 | 2.9 | 0.86 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.9 | 1.2 | -0.33 |
| Endometriosis | 1.8 | 0.8 | 1.25 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 2 | 1.3 | 0.54 |
| erectile dysfunction | 0.9 | 0.9 | |
| Fibromyalgia | 1 | 1.4 | -0.4 |
| Functional constipation / chronic idiopathic constipation | 4.2 | 2.8 | 0.5 |
| gallstone disease (gsd) | 2.1 | 2.1 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 0.3 | 3 |
| Generalized anxiety disorder | 1.4 | 0.6 | 1.33 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.1 | 2.1 | |
| Graves' disease | 1 | 0.9 | 0.11 |
| Gulf War Syndrome | 0.3 | 1.2 | -3 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 1.2 | 0.3 | 3 |
| Heart Failure | 2.1 | 0.4 | 4.25 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.2 | 0.3 | -0.5 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
| hyperglycemia | 1.1 | 0.7 | 0.57 |
| hypertension (High Blood Pressure | 2.5 | 2.4 | 0.04 |
| Hypoxia | 1.5 | 1.5 | |
| IgA nephropathy (IgAN) | 1.3 | 2.3 | -0.77 |
| Inflammatory Bowel Disease | 4 | 4.1 | -0.02 |
| Insomnia | 0.9 | 1.2 | -0.33 |
| Intelligence | 1.1 | 0.5 | 1.2 |
| Intracranial aneurysms | 1 | 1 | |
| Irritable Bowel Syndrome | 3.5 | 3.1 | 0.13 |
| ischemic stroke | 1.5 | 1.2 | 0.25 |
| Liver Cirrhosis | 3.6 | 1.1 | 2.27 |
| Long COVID | 4 | 2.8 | 0.43 |
| Lung Cancer | 1.2 | 0.3 | 3 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.3 | 2 |
| ME/CFS with IBS | 0.3 | 0.3 | 0 |
| ME/CFS without IBS | 0.3 | 0.9 | -2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.9 | 0.9 | |
| Metabolic Syndrome | 3.6 | 3.4 | 0.06 |
| Mood Disorders | 4.6 | 2.9 | 0.59 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
| Multiple Sclerosis | 2.5 | 3.1 | -0.24 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| myasthenia gravis | 0.9 | 0.9 | |
| neuropathic pain | 1.3 | -1.3 | |
| Neuropathy (all types) | 0.3 | 1.6 | -4.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.1 | 0.9 | 2.44 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 4.1 | 2.5 | 0.64 |
| obsessive-compulsive disorder | 4.8 | 1.7 | 1.82 |
| Osteoarthritis | 1.8 | 0.9 | 1 |
| Osteoporosis | 1.2 | 0.6 | 1 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 3.6 | 3.2 | 0.13 |
| Polycystic ovary syndrome | 4.9 | 1.8 | 1.72 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.9 | -2 |
| Primary sclerosing cholangitis | 1 | 1.3 | -0.3 |
| Psoriasis | 1.4 | 1.9 | -0.36 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3 | 1.2 | 1.5 |
| Rosacea | 0.3 | 0.3 | |
| Schizophrenia | 2.2 | 1 | 1.2 |
| scoliosis | 0.2 | 0.3 | -0.5 |
| Sjögren syndrome | 2.1 | 1.6 | 0.31 |
| Sleep Apnea | 0.3 | 0.6 | -1 |
| Slow gastric motility / Gastroparesis | 0.8 | 0.8 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0.8 | |
| Stress / posttraumatic stress disorder | 0.9 | 0.7 | 0.29 |
| Systemic Lupus Erythematosus | 2.5 | 0.8 | 2.13 |
| Tic Disorder | 1.5 | 0.5 | 2 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 3.3 | 1.5 | 1.2 |
| Type 2 Diabetes | 4.8 | 3.9 | 0.23 |
| Ulcerative colitis | 3 | 4.9 | -0.63 |
| Unhealthy Ageing | 1.8 | 0.8 | 1.25 |
| Vitiligo | 1.9 | 0.4 | 3.75 |
